Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dolby Laboratories, Inc.DLB · Entity 2518 | Director · President and CEO | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dolby Laboratories, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | Direct | 145,252 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Gift · Disposed 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | IndirectBy a trust | 145,252 |
Reported balance
After 2026-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-05 · Gift · Acquired 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
Filing footnotes · ownership attribution and instrument terms
F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5.
F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter.
F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2019 Filed Feb 11, 2019 21:05 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 44,328 | $0.00 Strike: $28.24 | $0.00 |
DisclosureSEC source: 0001209191-19-009147 · doc4.xml · derivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 50,948 Underlying: Class A Common Stock · 44,328 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted for a total of 260,605 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2011, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:05 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 886 | $64.68 | $57,306.48 |
DisclosureSEC source: 0001209191-19-009147 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:05 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 43,442 | $64.02 | $2,781,013.48 |
DisclosureSEC source: 0001209191-19-009147 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 33,781 F2 · price: The shares were sold in multiple transactions at prices ranging from $63.54 to $64.36, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:05 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 44,328 | $28.24 | $1,251,822.72 |
DisclosureSEC source: 0001209191-19-009147 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 77,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:05 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 5,672 | $64.19 | $364,070.37 |
DisclosureSEC source: 0001209191-19-009147 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F1 · price: The shares were sold in multiple transactions at prices ranging from $64 to $64.68, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 20:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 600 | $65.16 | $39,096.00 |
DisclosureSEC source: 0001209191-18-063596 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 38,567 F6 · price: This transaction was executed in multiple trades at prices ranging from $65.15 to $65.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 20:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 17,001 | $64.56 | $1,097,577.76 |
DisclosureSEC source: 0001209191-18-063596 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 39,167 F5 · price: This transaction was executed in multiple trades at prices ranging from $64.15 to $65.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 20:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantEmployee Stock Option (Right to Buy) · Derivative | 164,000 | $0.00 Strike: $64.60 | $0.00 |
DisclosureSEC source: 0001209191-18-063596 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,000 Underlying: Class A Common Stock · 164,000 shares Expires 2028-12-17 F8 · derivative.exercise_date: This option was granted for a total of 164,000 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 17, 2018, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 20:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantPerformance-Based Stock Option (Right to Buy) · Derivative | 82,000 | $0.00 Strike: $64.60 | $0.00 |
DisclosureSEC source: 0001209191-18-063596 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Class A Common Stock · 82,000 shares Expires 2025-12-17 F7 · derivative.exercise_date: The vesting of this performance-based stock option ("PSO") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 17, 2018 and ending December 17, 2021. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 125% of the target award amount based on total shareholder return at the end of the three-year performance period. The actual PSO award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 20:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantClass A Common Stock | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063596 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,664 F3 · acquired: Award represents a total of 41,000 restricted stock units granted under the terms of the Issuer's 2005 Stock Plan. Under the terms of the restricted stock unit grant agreement, 1/4 of the total number of units shall vest on each anniversary of December 17, 2018. Each unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon vesting. F4 · balance_after: Shares held following the reported transactions include 109,664 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 20:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 22,891 | $66.17 | $1,514,697.47 |
DisclosureSEC source: 0001209191-18-063596 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,664 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F2 · balance_after: Shares held following the reported transactions include 68,664 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:24 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $28.24 | $0.00 |
DisclosureSEC source: 0001209191-18-048496 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 95,276 Underlying: Class A Common Stock · 30,000 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted for a total of 260,605 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2011, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:24 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 30,000 | $70.00 | $2,100,000.00 |
DisclosureSEC source: 0001209191-18-048496 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:24 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 30,000 | $28.24 | $847,200.00 |
DisclosureSEC source: 0001209191-18-048496 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 100 | $64.97 | $6,497.00 |
DisclosureSEC source: 0001209191-18-045276 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 14,900 | $64.47 | $960,631.31 |
DisclosureSEC source: 0001209191-18-045276 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,995 F1 · price: This transaction was executed in multiple trades at prices ranging from $63.965 to $64.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $62.32 | $0.00 |
DisclosureSEC source: 0001209191-18-034675 · doc4.xml · derivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 180,000 Underlying: Class A Common Stock · 180,000 shares Expires 2027-12-15 F1 · kind: Effective June 1, 2018 the Reporting Person transferred this option as a gift to a revocable trust. F5 · derivative.exercise_date: This option was granted for a total of 180,000 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2017, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $62.32 | $0.00 |
DisclosureSEC source: 0001209191-18-034675 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 180,000 shares Expires 2027-12-15 F1 · kind: Effective June 1, 2018 the Reporting Person transferred this option as a gift to a revocable trust. F5 · derivative.exercise_date: This option was granted for a total of 180,000 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2017, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftPerformance-Based Stock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $62.32 | $0.00 |
DisclosureSEC source: 0001209191-18-034675 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 90,000 Underlying: Class A Common Stock · 90,000 shares Expires 2024-12-15 F1 · kind: Effective June 1, 2018 the Reporting Person transferred this option as a gift to a revocable trust. F4 · derivative.exercise_date: The vesting of this performance-based stock option ("PSO") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2017 and ending December 15, 2020. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 125% of the target award amount based on total shareholder return at the end of the three-year performance period. The actual PSO award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftPerformance-Based Stock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $62.32 | $0.00 |
DisclosureSEC source: 0001209191-18-034675 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 90,000 shares Expires 2024-12-15 F1 · kind: Effective June 1, 2018 the Reporting Person transferred this option as a gift to a revocable trust. F4 · derivative.exercise_date: The vesting of this performance-based stock option ("PSO") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2017 and ending December 15, 2020. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 125% of the target award amount based on total shareholder return at the end of the three-year performance period. The actual PSO award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 194,399 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-18-034675 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 194,399 Underlying: Class A Common Stock · 194,399 shares Expires 2026-12-15 F1 · kind: Effective June 1, 2018 the Reporting Person transferred this option as a gift to a revocable trust. F3 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2016, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 194,399 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-18-034675 · doc4.xml · derivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 194,399 shares Expires 2026-12-15 F1 · kind: Effective June 1, 2018 the Reporting Person transferred this option as a gift to a revocable trust. F3 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2016, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftPerformance-Based Stock Option (Right to Buy) · Derivative | 97,199 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-18-034675 · doc4.xml · derivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 97,199 Underlying: Class A Common Stock · 97,199 shares Expires 2023-12-15 F1 · kind: Effective June 1, 2018 the Reporting Person transferred this option as a gift to a revocable trust. F2 · derivative.exercise_date: The vesting of this performance-based stock option ("PSO") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2016 and ending December 15, 2019. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 125% of the target award amount based on total shareholder return at the end of the three-year performance period. The actual PSO award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 16:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftPerformance-Based Stock Option (Right to Buy) · Derivative | 97,199 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-18-034675 · doc4.xml · derivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 97,199 shares Expires 2023-12-15 F1 · kind: Effective June 1, 2018 the Reporting Person transferred this option as a gift to a revocable trust. F2 · derivative.exercise_date: The vesting of this performance-based stock option ("PSO") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2016 and ending December 15, 2019. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 125% of the target award amount based on total shareholder return at the end of the three-year performance period. The actual PSO award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:46 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 15,000 | $59.58 | $893,691.00 |
DisclosureSEC source: 0001209191-18-027659 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 47,895 F1 · price: This transaction was executed in multiple trades at prices ranging from $59.06 to $59.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 20:15 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 18,548 | $0.00 Strike: $28.24 | $0.00 |
DisclosureSEC source: 0001209191-18-009827 · doc4.xml · derivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 125,276 Underlying: Class A Common Stock · 18,548 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted for a total of 260,605 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2011, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 20:15 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 18,548 | $61.40 | $1,138,856.47 |
DisclosureSEC source: 0001209191-18-009827 · doc4.xml · nonDerivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 F4 · price: This transaction was executed in multiple trades at prices ranging from $60.65 to $61.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 20:15 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 18,548 | $28.24 | $523,795.52 |
DisclosureSEC source: 0001209191-18-009827 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 81,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 20:15 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $28.24 | $0.00 |
DisclosureSEC source: 0001209191-18-009827 · doc4.xml · derivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 143,824 Underlying: Class A Common Stock · 50,000 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted for a total of 260,605 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2011, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 20:15 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 2,200 | $60.65 | $133,427.14 |
DisclosureSEC source: 0001209191-18-009827 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 F3 · price: This transaction was executed in multiple trades at prices ranging from $60.4301 to $60.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 20:15 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 7,896 | $59.92 | $473,159.90 |
DisclosureSEC source: 0001209191-18-009827 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 65,095 F2 · price: This transaction was executed in multiple trades at prices ranging from $59.4201 to $60.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 20:15 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 39,904 | $58.75 | $2,344,308.12 |
DisclosureSEC source: 0001209191-18-009827 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 72,991 F1 · price: This transaction was executed in multiple trades at prices ranging from $58.38 to $59.3601. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 20:15 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 50,000 | $28.24 | $1,412,000.00 |
DisclosureSEC source: 0001209191-18-009827 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 112,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $28.24 | $0.00 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · derivative · entry 16 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 193,824 Underlying: Class A Common Stock · 50,000 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: This option was granted for a total of 260,605 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2011, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 2,901 | $62.69 | $181,857.89 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 12 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 F9 · price: This transaction was executed in multiple trades at prices ranging from $62.33 to $63.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 25,929 | $61.73 | $1,600,610.13 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 11 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 65,796 F8 · price: This transaction was executed in multiple trades at prices ranging from $61.26 to $62.1901. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 15,030 | $60.87 | $914,874.60 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 10 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 91,725 F7 · price: This transaction was executed in multiple trades at prices ranging from $60.26 to $61.2501. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 6,140 | $60.05 | $368,725.42 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 106,755 F6 · price: This transaction was executed in multiple trades at prices ranging from $59.22 to $60.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 50,000 | $28.24 | $1,412,000.00 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 112,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,781 | $0.00 Strike: $28.24 | $0.00 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · derivative · entry 15 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 243,824 Underlying: Class A Common Stock · 16,781 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: This option was granted for a total of 260,605 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2011, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,655 | $0.00 Strike: $28.66 | $0.00 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · derivative · entry 14 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 0 Underlying: Class A Common Stock · 12,655 shares Expires 2019-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: This option was granted for a total of 134,757 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of March 16, 2009, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 16,781 | $63.20 | $1,060,483.69 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 F5 · price: This transaction was executed in multiple trades at prices ranging from $62.5801 to $63.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 16,781 | $28.24 | $473,895.44 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 79,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 2,400 | $63.76 | $153,033.12 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 F4 · price: This transaction was executed in multiple trades at prices ranging from $63.67 to $63.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 10,255 | $63.48 | $650,936.13 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 65,295 F3 · price: This transaction was executed in multiple trades at prices ranging from $62.665 to $63.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 12,655 | $28.66 | $362,692.30 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 75,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 2,501 | $63.73 | $159,387.23 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 F2 · price: This transaction was executed in multiple trades at prices ranging from $63.62 to $63.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:23 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 18,063 | $63.28 | $1,143,021.22 |
DisclosureSEC source: 0001209191-18-009029 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 65,396 F1 · price: This transaction was executed in multiple trades at prices ranging from $62.62 to $63.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 19, 2017 Filed Dec 19, 2017 20:59 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 6,460 | $62.42 | $403,241.60 |
DisclosureSEC source: 0001209191-17-066575 · doc4.xml · nonDerivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 83,459 F7 · price: This transaction was executed in multiple trades at prices ranging from $62 to $62.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 20:59 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 11,130 | $62.47 | $695,249.92 |
DisclosureSEC source: 0001209191-17-066575 · doc4.xml · nonDerivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 89,919 F6 · price: This transaction was executed in multiple trades at prices ranging from $62.185 to $62.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.